CN105358156A - 双重mek/pi3k抑制剂和使用其的治疗方法 - Google Patents

双重mek/pi3k抑制剂和使用其的治疗方法 Download PDF

Info

Publication number
CN105358156A
CN105358156A CN201480014555.XA CN201480014555A CN105358156A CN 105358156 A CN105358156 A CN 105358156A CN 201480014555 A CN201480014555 A CN 201480014555A CN 105358156 A CN105358156 A CN 105358156A
Authority
CN
China
Prior art keywords
alkyl
compound
independently
hydrogen
mek
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480014555.XA
Other languages
English (en)
Chinese (zh)
Inventor
B.D.罗斯
M.范多尔特
C.怀特黑德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of CN105358156A publication Critical patent/CN105358156A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480014555.XA 2013-03-13 2014-03-12 双重mek/pi3k抑制剂和使用其的治疗方法 Pending CN105358156A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779462P 2013-03-13 2013-03-13
US61/779462 2013-03-13
PCT/US2014/023860 WO2014164942A1 (en) 2013-03-13 2014-03-12 Dual mek/pi3k inhibitors and therapeutic methods using the same

Publications (1)

Publication Number Publication Date
CN105358156A true CN105358156A (zh) 2016-02-24

Family

ID=51659015

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480014555.XA Pending CN105358156A (zh) 2013-03-13 2014-03-12 双重mek/pi3k抑制剂和使用其的治疗方法

Country Status (6)

Country Link
US (1) US9611258B2 (https=)
EP (1) EP2968345B1 (https=)
JP (1) JP6315848B2 (https=)
CN (1) CN105358156A (https=)
CA (1) CA2901613C (https=)
WO (1) WO2014164942A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563088A (zh) * 2016-07-06 2019-04-02 密歇根大学董事会 MEK/PI3K和mTOR/MEK/PI3K生物途径的多功能抑制剂和使用多功能抑制剂的治疗方法
CN111135309A (zh) * 2020-01-15 2020-05-12 重庆大学 一种核壳结构的替拉扎明药物载体及其制备方法和应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
US9968604B2 (en) * 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
US20190038713A1 (en) 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
WO2018111902A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
AU2018316175B2 (en) * 2017-08-11 2023-02-23 The Regents Of The University Of Michigan Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K3k/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds
EP3768698B1 (en) 2018-03-19 2025-02-12 MultiVir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
JP7582694B2 (ja) 2020-01-10 2024-11-13 イミューニヤリング コーポレーション Ｍｅｋ阻害剤及びその治療的使用
AR121078A1 (es) 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
JP2025503606A (ja) * 2022-01-06 2025-02-04 イミューニヤリング コーポレーション Ｍｅｋ免疫腫瘍学阻害剤及びそれらの治療的使用
WO2024102859A1 (en) * 2022-11-09 2024-05-16 Immuneering Corporation Mek immune oncology inhibitors and therapeutic uses thereof
WO2025010287A2 (en) * 2023-07-03 2025-01-09 Immuneering Corporation Mek immune oncology inhibitors and therapeutic uses thereof
WO2025114495A1 (en) * 2023-11-28 2025-06-05 Universität Basel Pi3k inhibitors and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1446197A (zh) * 2000-07-19 2003-10-01 沃尼尔·朗伯公司 4－碘苯氨基苯氧肟酸的氧合酯
WO2011135520A1 (en) * 2010-04-30 2011-11-03 University Of Basel Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferative disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
WO2008032033A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032060A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
US8569378B2 (en) * 2007-07-20 2013-10-29 Toshiyuki Sakai p27 protein inducer
EP2276750A2 (en) 2008-03-27 2011-01-26 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
KR20110028651A (ko) * 2008-07-11 2011-03-21 노파르티스 아게 (ａ) 포스포이노시타이드 3-키나제 억제제 및 (ｂ) ｒａｓ/ｒａｆ/ｍｅｋ 경로의 조절제의 조합물
SG174527A1 (en) 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
US20110166191A1 (en) * 2010-01-07 2011-07-07 Shijun Zhang 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazolidine-2,4-dione and its derivatives as multiple signaling pathway inhibitors and for the treatment of cancer
ES2791716T3 (es) * 2010-12-14 2020-11-05 Univ Maryland Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1446197A (zh) * 2000-07-19 2003-10-01 沃尼尔·朗伯公司 4－碘苯氨基苯氧肟酸的氧合酯
WO2011135520A1 (en) * 2010-04-30 2011-11-03 University Of Basel Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferative disorders

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563088A (zh) * 2016-07-06 2019-04-02 密歇根大学董事会 MEK/PI3K和mTOR/MEK/PI3K生物途径的多功能抑制剂和使用多功能抑制剂的治疗方法
CN109563088B (zh) * 2016-07-06 2022-10-11 密歇根大学董事会 MEK/PI3K和mTOR/MEK/PI3K的多功能抑制剂和治疗用途
CN111135309A (zh) * 2020-01-15 2020-05-12 重庆大学 一种核壳结构的替拉扎明药物载体及其制备方法和应用

Also Published As

Publication number Publication date
JP6315848B2 (ja) 2018-04-25
CA2901613A1 (en) 2014-10-09
EP2968345A4 (en) 2016-08-17
WO2014164942A1 (en) 2014-10-09
US20160002212A1 (en) 2016-01-07
CA2901613C (en) 2020-10-20
EP2968345B1 (en) 2017-12-13
JP2016516702A (ja) 2016-06-09
EP2968345A1 (en) 2016-01-20
US9611258B2 (en) 2017-04-04

Similar Documents

Publication Publication Date Title
CN105358156A (zh) 双重mek/pi3k抑制剂和使用其的治疗方法
JP7475062B2 (ja) ＭＥＫ／ＰＩ３Ｋ及びｍＴＯＲ／ＭＥＫ／ＰＩ３Ｋ生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法
TW202007396A (zh) Bcl-2抑制劑或Bcl-2/Bcl-xL抑制劑與BTK抑制劑的組合產品及其在預防和/或治療疾病中的用途
KR20180132618A (ko) 아미노티아졸 화합물 및 이의 용도
EP3617195B1 (en) Novel tetrahydronaphthyl urea derivatives as inhibitors of tropomyosin receptor kinase a for the treatment of pain
CN102317290A (zh) Stat3抑制剂及使用stat3抑制剂的治疗方法
TW202019409A (zh) Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或bcl-2抑制劑與chop聯合用藥的協同抗腫瘤作用
CN115698014A (zh) 用于治疗医学病症的细胞周期蛋白依赖性激酶抑制化合物
CN116323590A (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
RU2758259C2 (ru) Соединение формулы (I), фармацевтическая композиция, применение соединения формулы (I) для лечения гематологических и/или пролиферативных нарушений
BRPI0609667A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
JP3810017B2 (ja) 縮合ヘテロアリール誘導体
TWI839385B (zh) 肥胖症的治療
CN121591697A (zh) 靶向anxa3蛋白的1,4-苯二氮䓬类化合物及其药用用途
WO2024174949A1 (zh) 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用
AU2022399786A1 (en) Compounds
WO2022171018A1 (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: michigan

Applicant after: The Regents of the Univ. of Michigan

Address before: Michigan

Applicant before: The Regents of The Univ. of Michigan

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160224